05 Cardiovascular system drugs The sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin (Andaton; AstraZeneca) has been on the market as a hypoglycemic agent for nearly 10 years. Another indication of the […]
05 Cardiovascular system drugs The sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin (Andaton; AstraZeneca) has been on the market as a hypoglycemic agent for nearly 10 years. Another indication of the […]